Amneal Pharmaceuticals (AMRX) Earnings Date, Estimates & Call Transcripts $8.53 -0.36 (-4.05%) As of 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Amneal Pharmaceuticals Latest Earnings SummaryActual EPS (Feb. 28) $0.12 Missed By -$0.03 Consensus EPS (Feb. 28) $0.15 Amneal Pharmaceuticals released Q4 2024 earnings on February 28, 2025, reporting an EPS of $0.12, which missed analysts' consensus estimates of $0.15 by $0.03. Quarterly revenue was reported to be $730.52 million, above analyst estimates of $708.21 million. With a trailing EPS of -$0.38, Amneal Pharmaceuticals' earnings are expected to grow 13.21% next year, from $0.53 to $0.60 per share. Conference CallConference Call TranscriptEarnings Press ReleaseEarnings Slide DeckPowered by Get Amneal Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amneal Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAMRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AMRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Amneal Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:$0.53 EPSNext Year EPS Consensus Estimate: $0.60 EPS Remove Ads Amneal Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails2/28/2025Q4 2024$0.15$0.12 -$0.03-$0.10$708.21M$730.52M8/9/2024Q2 2024$0.11$0.15+$0.04$0.28$657.43M$701.78M5/3/2024Q1 2024$0.08$0.12+$0.04$0.54$623.08M$659.19M3/1/2024Q4 2023$0.05$0.12+$0.07$0.64$630.67M$616.98M11/7/2023Q3 2023$0.10$0.17+$0.07$0.28$613.74M$620.04M8/4/2023Q2 2023$0.08$0.16+$0.08$0.24$562.49M$599.05M5/5/2023Q1 2023$0.09$0.10+$0.01$0.25$555.00M$557.54M Amneal Pharmaceuticals Earnings - Frequently Asked Questions When did Amneal Pharmaceuticals announce their last quarterly earnings? Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earning data on Friday, February 28, 2025. Learn more on AMRX's earnings history. What guidance has Amneal Pharmaceuticals issued on next quarter's earnings? Amneal Pharmaceuticals issued an update on its FY 2025 earnings guidance on Friday, February, 28th. The company provided earnings per share guidance of 0.650-0.700 for the period, compared to the consensus EPS estimate of 0.710. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $2.9 billion. Did Amneal Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Amneal Pharmaceuticals (NASDAQ:AMRX) missed the analysts' consensus estimate of $0.15 by $0.03 with a reported earnings per share (EPS) of $0.12. Learn more on analysts' earnings estimate vs. AMRX's actual earnings. How can I listen to Amneal Pharmaceuticals's earnings conference call? The conference call for Amneal Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Amneal Pharmaceuticals's conference call transcript? The conference call transcript for Amneal Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Amneal Pharmaceuticals generate each year? Amneal Pharmaceuticals (NASDAQ:AMRX) has a recorded annual revenue of $2.79 billion. How much profit does Amneal Pharmaceuticals generate each year? Amneal Pharmaceuticals (NASDAQ:AMRX) has a recorded net income of -$83.99 million. AMRX has generated -$0.38 earnings per share over the last four quarters. What is Amneal Pharmaceuticals's EPS forecast for next year? Amneal Pharmaceuticals's earnings are expected to grow from $0.53 per share to $0.60 per share in the next year, which is a 13.21% increase. More Earnings Resources from MarketBeat Related Companies Ascendis Pharma A/S Earnings Sarepta Therapeutics Earnings Vaxcyte Earnings Qiagen Earnings Roivant Sciences Earnings Revolution Medicines Earnings Lantheus Earnings Legend Biotech Earnings TG Therapeutics Earnings BridgeBio Pharma Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of Earnings Remove Ads This page (NASDAQ:AMRX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMRX Stock Free AMRX Stock Alerts